ArticleJournal of thrombosis and haemostasis : JTH2020
The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations.
Article in Journal of thrombosis and haemostasis : JTH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Effects of Fibrinogen on Tenecteplase Treatment in Acute Ischaemic Stroke After 4.5 Hours of Symptom Onset: A Post Hoc Analysis of the TRACE-III Trial.Neurology and therapy · 2026Article
- Vitamin K Deficiency and Thrombophilia in Pregnancy: A Fine Balance Between Bleeding and Thrombus Formation-Insights from a Narrative Review.International journal of molecular sciences · 2026Review
- Platelet hypoaggregation in septic shock: temporal dynamics and association with multiorgan failure-a propensity score-matched cohort study.BMC anesthesiology · 2026Article
- Protective Effect of Factor XIII Intron-K G Allele on Subclinical Vascular Disease.International journal of molecular sciences · 2025Article
- Review
- Investigation of the relationship between venous thromboembolism and thrombophilic variants.Revista da Associacao Medica Brasileira (1992) · 2025Article
- A nomogram model to predict non-retrieval of short-term retrievable inferior vena cava filters.Frontiers in cardiovascular medicine · 2024Article
- Fibrinogen and fibrin: synthesis, structure, and function in health and disease.Journal of thrombosis and haemostasis : JTH · 2023Review
- An Exploratory Study Using Next-Generation Sequencing to Identify Prothrombotic Variants in Patients with Cerebral Vein Thrombosis.International journal of molecular sciences · 2023Article
- Transglutaminase Activities of Blood Coagulant Factor XIII Are Dependent on the Activation Pathways and on the Substrates.Thrombosis and haemostasis · 2023Article
- Genetic Markers for Thrombophilia and Cardiovascular Disease Associated with Multiple Sclerosis.Biomedicines · 2022Article
- Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.Arteriosclerosis, thrombosis, and vascular biology · 2022Review
- Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.Journal of thrombosis and haemostasis : JTH · 2021Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundFactor XIII (FXIII) promotes fibrin crosslinking and red blood cell (RBC) retention in clots. The FXIII-A polymorphism, Val34Leu, is associated with protection against venous thrombosis. This effect is hypothesized to result from fibrinogen concentration-dependent changes in fibrin structure. Effects of the FXIII-A Val34Leu polymorphism in whole blood clots have not been investigated.
aimCharacterize effects of FXIII-A Val34Leu polymorphism and fibrinogen on whole blood clots.
methodsWe isolated platelet-poor plasmas from human donors (FXIII
resultsClot mass was associated with age, fibrinogen, prothrombin time, and thrombin generation. Clots reconstituted with plasmas from individuals with FXIII-A
conclusionsFXIII 34Leu mitigates the effect of elevated fibrinogen on whole blood clot mass. The Val34Leu polymorphism may protect against venous thrombosis by reducing clot mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.